ArticleNanomaterials (Basel, Switzerland)2025
Albumin-Coated Copper Oxide Nanoparticles for Radiosensitization of Human Glioblastoma Cells Under Clinically Relevant X-Ray Irradiation.
Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026Review
- A Comprehensive Review on Copper Oxide Nanoparticles: Physicochemical Parameters, Pharmacological Potential and Pathophysiological Effects.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Glioblastoma (GBM) is the most aggressive and treatment-resistant primary brain tumor in adults. Despite current multimodal therapies, including surgery, radiation, and temozolomide chemotherapy, patient outcomes remain poor. Enhancing tumor radiosensitivity through biocompatible nanomaterials could provide a promising integrative strategy for improving therapeutic effectiveness. This study aims to evaluate the potential of bovine serum albumin-coated copper oxide nanoparticles (BSA@CuO-NPs) to enhance radiosensitivity in U87-MG cells under clinically relevant X-ray irradiation. In brief, BSA@CuO-NPs were synthesized via carbodiimide crosslinking and characterized by DLS, SEM, and zeta potential analysis. U87-MG cells were treated with BSA@CuO-NPs alone or in combination with X-ray irradiation (2 Gy). Cytotoxicity was assessed using the MTT assay, while radiosensitization was evaluated through clonogenic survival analysis. Apoptosis induction and DNA damage were analyzed via Annexin V staining and γ-H2AX immunofluorescence, respectively. The results revealed that BSA@CuO-NPs showed good colloidal stability and biocompatibility compared with uncoated CuO-NPs. When combined with irradiation, BSA@CuO-NPs significantly decreased clonogenic survival (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.